Stock GMAB GENMAB A/S
Add to a list
To use this feature you must be a member
Log inSign up

Highlights Genmab A/S Nasdaq

Equities

GMAB

US3723032062

Real-time Estimate Cboe BZX
Other stock markets
 13:39:05 2024-06-26 EDT 		5-day change 1st Jan Change
25.72 USD -0.23% Intraday chart for Genmab A/S -0.71% -19.29%
06-10 Transcript : Genmab A/S Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM
06-04 Truist Securities Raises Price Target on Genmab to $53 From $50, Maintains Buy Rating MT

Highlights

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Genmab's Tisotumab Shows 'Encouraging' Antitumor Activity in Phase 2 Head, Neck Cancer Study
MT
Genmab A/S Announces Data from the Phase 2 Innovatv 207 Trial, Investigating Tisotumab Vedotin
CI
Genmab A S and BioNTech SE Announces Initial Data from the Ongoing Phase 2 Trial
CI
Genmab Announces Initial Data from Phase 2 Cancer Treatment Trial
MT
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma
CI
Genmab A/S and Biontech SE Announce Initial Data from the Phase 2 Gct1046-04 Trial (NCT05117242) Evaluating Acasunlimab
CI
Genmab A/S Reaffirms Financial Guidance for 2024
CI
Genmab A/S completed the acquisition of ProfoundBio, Inc.
CI
Genmab CEO Says Western Firms Should Tap Into China's 'Impressive Innovation'
MT
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association Congress
CI
GENMAB : A good start to 2024; guidance unchanged
Alphavalue
Genmab Posts Q1 Net Profit Surge; Revenue Jumps
MT
Genmab Reports Higher Interim Q1 Results; Maintains 2024 Guidance
MT
Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 1, 2021.
CI
Tranche Update on Genmab A/S's Equity Buyback Plan announced on March 25, 2024.
CI
Genmab A/S Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Pfizer, Genmab Say FDA Approves Tivak to Treat Cervical Cancer
MT
Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer
CI
Genmab, Johnson & Johnson Logs Higher Q1 Sales for Blood Cancer Drug
MT
Health Care Slips on Risk Bias -- Health Care Roundup
DJ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GMAB Stock
  4. GMAB Stock
  5. News Genmab A/S
  6. Highlights